Addressing Dementia Via Agitation-Centered Evaluation (ADVANCE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03226522|
Recruitment Status : Recruiting
First Posted : July 21, 2017
Last Update Posted : January 14, 2020
|Condition or disease||Intervention/treatment||Phase|
|Agitation in Patients With Dementia of the Alzheimer's Type Alzheimer Disease Agitation,Psychomotor||Drug: AXS-05 Drug: Bupropion Drug: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||435 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type|
|Actual Study Start Date :||July 13, 2017|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2020|
AXS-05 tablets taken by mouth for 5 weeks.
Active Comparator: Bupropion
Bupropion tablets taken by mouth for 5 weeks.
Placebo Comparator: Placebo
Placebo tablets taken by mouth for 5 weeks.
- Cohen-Mansfield Agitation Inventory (CMAI) [ Time Frame: 5 weeks ]Change from Baseline to Week 5 in the CMAI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03226522
|Contact: Axsome Clinical Trials||+1 (212) 332-3241||ADVANCEemail@example.com|